Vanguard Global Advisers
PLYX icon

Vanguard Global Advisers’s Polaryx Therapeutics Inc PLYX Stock Holding History

Vanguard Global Advisers’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.1K Hold
6,318
– – ﹤0.01% 3459
2026
Q2 		$16.8K Hold
6,318
– – ﹤0.01% 3375
2026
Q1 		$47.8K Buy
+6,318
New +$40.8K ﹤0.01% 3046

Other funds holding PLYX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $87.3B AUM 22.01% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Vanguard Global Advisers's PLYX Position: Q3 2026 in Review

Vanguard Global Advisers held its Polaryx Therapeutics Inc (PLYX) position steady in Q3 2026 at 6,318 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3459.

Vanguard Global Advisers first reported a position in PLYX in Q1 2026 and has held it in 3 quarters since. The position peaked at $47.8K in Q1 2026. 11 funds tracked by Wall St. Rank hold PLYX as of Q3 2026.

  • Vanguard Global Advisers held 6,318 shares of Polaryx Therapeutics Inc worth $13.1K as of Q3 2026.
  • Vanguard Global Advisers left its Polaryx Therapeutics Inc share count unchanged in Q3 2026.
  • Polaryx Therapeutics Inc made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3459 holding.
  • Vanguard Global Advisers first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Polaryx Therapeutics Inc position peaked at $47.8K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.